We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid RSV Tests Reduces Antibiotic Prescribing in Kids

By LabMedica International staff writers
Posted on 13 Mar 2026

Respiratory syncytial virus (RSV) is a major cause of viral lower respiratory tract infections in young children. More...

Although antibiotics do not treat viral infections, they are frequently prescribed in outpatient pediatric settings where diagnostic tools to confirm viral causes are often unavailable. Now, a new study suggests that rapid antigen diagnostic tests for RSV may significantly reduce unnecessary antibiotic prescribing in young children.

In the study, investigators from the University of Milan-Bicocca (Milan, Italy) used data from a network of more than 200 family pediatricians in Italy to evaluate the use of combined rapid antigen diagnostic tests (Ag-RDTs) for COVID-19, influenza, and RSV in children aged 9 to 36 months presenting with suspected viral lower respiratory tract infections, including bronchiolitis.

A total of 256 children (median age 15 months; 52% male) were included in the study. Among them, 79 children (30.9%) tested positive for RSV, while 177 children (69.1%) tested negative. Antibiotic prescribing was significantly lower among RSV-positive children compared with RSV-negative children. The rate of antibiotic prescriptions was 0.18 per 10 person-days for RSV-positive cases versus 0.29 for RSV-negative cases.

Overall, detection of RSV using rapid antigen tests was associated with a 48% lower risk of receiving at least one antibiotic prescription (relative risk 0.52). When researchers compared clinical data from two respiratory seasons before and after rapid test implementation, they observed a 39% reduction in antibiotic prescribing during the 2023–2024 season and a 46% reduction during the 2022–2023 season.

The findings, published in JAMA Network Open, suggest that rapid RSV diagnostic tests can improve clinical decision-making by confirming viral infections at the point of care. This allows clinicians to avoid unnecessary antibiotic prescriptions and supports broader antimicrobial stewardship efforts. Researchers emphasize that larger studies are needed to evaluate the cost-effectiveness of widespread rapid RSV testing and confirm whether the findings apply across different healthcare settings.

“By improving diagnostic accuracy at the point of care, Ag-RDTs can support more targeted treatment decisions and strengthen antimicrobial stewardship,” wrote the authors.

Related Links:
University of Milan-Bicocca


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.